A protective shield that's helping detect things early. Far earlier than during COVID.
In the long human struggle against invisible threats, Canada has committed $574 million to weave together a national web of early warning, rapid manufacturing, and shared knowledge — a quiet act of collective foresight announced in May 2024. Fourteen research institutions across the country will pursue nineteen initiatives, each one an attempt to compress the distance between the moment a new pathogen emerges and the moment a society can respond. The investment reflects a hard lesson from COVID: that the infrastructure for survival must be built in peacetime, not assembled in panic.
- The memory of COVID's slow, costly unraveling drives a $574 million federal bet that the next pandemic can be caught earlier — perhaps early enough to matter.
- A national network called Prepared will transform ordinary clinic visits into surveillance moments, collecting swabs from patients with respiratory symptoms and scanning them for pathogens no one has named yet.
- Artificial intelligence will comb through electronic health records for statistical whispers — the faint patterns of emerging illness that human attention alone would almost certainly miss.
- The Ottawa Hospital is building an RNA vaccine biomanufacturing centre with $59 million in federal support, designed to pivot from one therapeutic to another in weeks rather than months.
- The entire system — detection, manufacturing, biotechnology integration, international data-sharing — depends on provincial buy-in and sector coordination that has not yet been fully secured.
- Researchers are candid that another respiratory pandemic is a matter of when and what, not if, and that the only honest goal is to shrink the window between emergence and response.
On a Monday in May, the federal government announced it would send nearly $574 million to 14 research institutions working on 19 separate initiatives — each one a piece of a larger question: how does a country catch the next health crisis before it becomes uncontrollable?
The most tangible of these projects is Prepared, a national early-detection network that would turn emergency departments and primary-care clinics into early-warning sensors. With patient consent, staff would collect swabs from those arriving with respiratory symptoms and send them to labs to be screened not just for familiar illnesses but for anything unfamiliar — any signal that a new pathogen might be entering the human population. The network already spans six provinces, with ambitions to reach every corner of the country. Beyond the swabs, artificial intelligence will scan electronic health records for the kind of statistical patterns that human eyes tend to overlook. Dr. Andrew Pinto, the project's lead and a family physician at St. Michael's Hospital in Toronto, described it as building a protective shield — one that could detect threats far earlier than COVID allowed.
At the Ottawa Hospital, a second major initiative is taking shape: a biomanufacturing centre dedicated to RNA vaccines. The same technology that proved itself during COVID, Dr. Duncan Stewart argues, can be adapted to respond to future outbreaks across many infectious diseases — pivoting from one RNA therapeutic to a related vaccine in weeks rather than months. The Ottawa Hospital received $59 million for this work, with additional federal support flowing to biomanufacturing partners at McMaster, Dalhousie, and the Vaccine and Infectious Disease Organization in Saskatoon. Stewart's argument is that a distributed network of manufacturing capacity will be more resilient than any single centralized facility.
What the investments sketch together is a vision of pandemic preparedness as a system: detection networks feeding information to manufacturing hubs, biotechnology companies integrated from the start, AI scanning for patterns, and researchers sharing findings across borders. Pinto was candid about the uncertainty underlying all of it. Another respiratory pandemic, he said, is something he fully anticipates — the only unknowns are when and what. The infrastructure being built now is not meant to prevent that moment, but to compress it: to catch the threat while it is still small, still containable, still something a prepared society might manage. Whether it holds together will depend on whether provinces join, whether industry integrates as planned, and whether the system survives the long quiet years before it is needed.
On a Monday in May, the federal government announced it would distribute nearly $574 million across the country to fund research projects designed to catch the next health crisis before it spirals. The money will flow to 14 research institutions working on 19 separate initiatives, each one a piece of a larger puzzle: how to detect emerging threats faster, manufacture countermeasures more quickly, and build the infrastructure to respond before a virus becomes a pandemic.
One of the most concrete of these projects is called Prepared, a national network that will turn emergency departments and primary-care clinics into early-warning sensors. The idea is straightforward but ambitious. When patients arrive with respiratory symptoms, staff will ask permission to take swabs. Those samples will be sent to labs to be screened not just for known illnesses—influenza, COVID, RSV—but for anything unfamiliar, anything that might signal a new pathogen emerging into the human population. The network has already recruited researchers and institutions across British Columbia, Alberta, Manitoba, Ontario, Quebec, and Newfoundland and Labrador, with hopes of expanding to every province and territory.
Dr. Andrew Pinto, a family physician at St. Michael's Hospital in Toronto and the lead on the Prepared project, frames it as an act of prevention. "We should think of this like a protective shield that's helping detect things early," he said. "Far earlier than during COVID." The project received $18.9 million of the federal allocation. Beyond the swabs, Prepared will deploy artificial intelligence to scan electronic health records for patterns that might signal an emerging threat—the kind of statistical whisper that human eyes might miss. Biotechnology companies that manufacture rapid tests, drugs, and vaccines will be woven into the network so that if something new is detected, the response can begin immediately. Pinto emphasized that all swab samples will be used only with explicit patient consent.
A second major initiative is taking shape at the Ottawa Hospital, where researchers will build a new biomanufacturing centre focused on RNA vaccines. The technology proved its worth during COVID, and Dr. Duncan Stewart, CEO and scientific director of the Ottawa Hospital Research Institute, sees it as the foundation for responding to future outbreaks across multiple infectious diseases. The same facility, the same manufacturing process, can pivot from producing one RNA therapeutic to producing a related RNA vaccine within weeks rather than months. The Ottawa Hospital is receiving $59 million for this work, with additional federal support going to biomanufacturing partners at McMaster University in Hamilton, Dalhousie University in Halifax, and the Vaccine and Infectious Disease Organization in Saskatoon. Stewart argues that a distributed network of manufacturing capacity, rather than a single centralized facility, will be far more resilient and responsive.
What emerges from these investments is a vision of pandemic preparedness as a system rather than a single intervention. Early detection networks feed information to manufacturing hubs. Biotechnology companies are integrated into the detection process so they can begin development work the moment a threat is identified. Artificial intelligence scans for patterns humans might miss. Researchers across multiple countries will share findings to improve the odds of catching emerging pathogens wherever they first appear. The funding was announced by Soraya Martinez Ferrada, the minister responsible for the Economic Development Agency of Canada in Quebec, speaking on behalf of the ministers of innovation, science and industry, and health.
Pinto acknowledged the uncertainty at the heart of all this planning. "As a public health specialist and as a practising physician, I would very much anticipate there being another respiratory pandemic in the future," he said. "The challenge is we don't know when it will be or what it will be." That unknowability is precisely why the infrastructure matters. The goal is not to prevent the next pandemic—that may be impossible—but to compress the time between emergence and response, to catch it while it is still small, still containable, still manageable. Whether that vision becomes reality will depend on whether provinces and territories actually join the network, whether biotechnology companies integrate into the system as planned, and whether the infrastructure holds together in the years of relative quiet that will precede the next crisis.
Notable Quotes
We should think of this like a protective shield that's helping detect things early. Far earlier than during COVID.— Dr. Andrew Pinto, family physician and Prepared project lead
The same technology, the same manufacturing process we'll be putting in place for RNA therapeutics, can be used for RNA vaccines. So it allows us to very rapidly use the same facility to produce a related but different product for a pandemic purpose.— Dr. Duncan Stewart, CEO of Ottawa Hospital Research Institute
The Hearth Conversation Another angle on the story
Why does early detection matter so much? We have vaccines now. We have treatments.
Because by the time you know you need a vaccine, the virus is already spreading. Early detection buys you weeks or months to manufacture and distribute before the exponential curve takes over. That's the difference between a contained outbreak and a pandemic.
The Prepared network asks for patient consent to take swabs. That seems like it could slow things down.
It does, in a sense. But it's the only way people will actually participate. You can't build a detection system on data people don't want to give you. Consent is the price of trust, and you need trust for the system to work at scale.
Why is manufacturing capacity such a big deal? Can't companies just ramp up production when they need to?
Not at the speed we need. Building a facility takes years. Building the expertise takes longer. If you already have the infrastructure in place, the trained people, the supply chains—you can go from detecting a new virus to producing vaccines in weeks instead of years. That's the difference between managing a crisis and being overwhelmed by it.
The article mentions artificial intelligence scanning health records. What's it actually looking for?
Patterns that don't fit. Unusual clusters of symptoms, hospitalizations in unexpected places, cases that don't match any known illness. An AI can process millions of data points and flag anomalies a human epidemiologist might not see until much later. It's like having a thousand pairs of eyes watching at once.
Do you think this will actually work when the next pandemic comes?
That depends entirely on whether the system stays intact during the quiet years. It's easy to fund and staff something when people remember the last crisis. It's much harder to maintain it when there's no immediate threat. The real test isn't the technology—it's whether institutions and governments stay committed when the urgency fades.